

# Hans-Guido Wendel

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1036793/publications.pdf>

Version: 2024-02-01

45  
papers

5,854  
citations

172457

29  
h-index

265206

42  
g-index

48  
all docs

48  
docs citations

48  
times ranked

9646  
citing authors

#	ARTICLE	IF	CITATIONS
1	Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. <i>Nature</i> , 2004, 428, 332-337.	27.8	898
2	Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia. <i>Cancer Discovery</i> , 2018, 8, 958-971.	9.4	594
3	RNA G-quadruplexes cause eIF4A-dependent oncogene translation in cancer. <i>Nature</i> , 2014, 513, 65-70.	27.8	506
4	Dissecting eIF4E action in tumorigenesis. <i>Genes and Development</i> , 2007, 21, 000.2-000.	5.9	411
5	The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development. <i>Nature Medicine</i> , 2015, 21, 1199-1208.	30.7	359
6	Genome-wide RNA-mediated interference screen identifies miR-19 targets in Notch-induced T-cell acute lymphoblastic leukaemia. <i>Nature Cell Biology</i> , 2010, 12, 372-379.	10.3	316
7	Therapeutic suppression of translation initiation modulates chemosensitivity in a mouse lymphoma model. <i>Journal of Clinical Investigation</i> , 2008, 118, 2651-60.	8.2	272
8	A cooperative microRNA-tumor suppressor gene network in acute T-cell lymphoblastic leukemia (T-ALL). <i>Nature Genetics</i> , 2011, 43, 673-678.	21.4	244
9	GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	229
10	<i>CREBBP</i> Inactivation Promotes the Development of HDAC3-Dependent Lymphomas. <i>Cancer Discovery</i> , 2017, 7, 38-53.	9.4	218
11	Loss of the HVEM Tumor Suppressor in Lymphoma and Restoration by Modified CAR-T Cells. <i>Cell</i> , 2016, 167, 405-418.e13.	28.9	204
12	The H3K27me3 demethylase UTX is a gender-specific tumor suppressor in T-cell acute lymphoblastic leukemia. <i>Blood</i> , 2015, 125, 13-21.	1.4	168
13	The Eph-Receptor A7 Is a Soluble Tumor Suppressor for Follicular Lymphoma. <i>Cell</i> , 2011, 147, 554-564.	28.9	151
14	RiboDiff: detecting changes of mRNA translation efficiency from ribosome footprints. <i>Bioinformatics</i> , 2017, 33, 139-141.	4.1	134
15	Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Escape-Driven Relapse in Multiple Myeloma. <i>Blood Cancer Discovery</i> , 2020, 1, 146-154.	5.0	114
16	Targeting cap-dependent translation blocks converging survival signals by AKT and PIM kinases in lymphoma. <i>Journal of Experimental Medicine</i> , 2011, 208, 1799-1807.	8.5	103
17	Tumorigenic activity and therapeutic inhibition of Rheb GTPase. <i>Genes and Development</i> , 2008, 22, 2178-2188.	5.9	100
18	The Oncogenic Action of NRF2 Depends on De-glycation by Fructosamine-3-Kinase. <i>Cell</i> , 2019, 178, 807-819.e21.	28.9	96

#	ARTICLE	IF	CITATIONS
19	Emerging epigenetic-modulating therapies in lymphoma. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 494-507.	27.6	80
20	<i>EIF1AX</i> and <i>RAS</i> Mutations Cooperate to Drive Thyroid Tumorigenesis through ATF4 and c-MYC. <i>Cancer Discovery</i> , 2019, 9, 264-281.	9.4	57
21	MicroRNA-128-3p is a novel oncomiR targeting PHF6 in T-cell acute lymphoblastic leukemia. <i>Haematologica</i> , 2014, 99, 1326-1333.	3.5	55
22	Genetic and epigenetic inactivation of <i>SESTRIN1</i> controls mTORC1 and response to EZH2 inhibition in follicular lymphoma. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	52
23	Forward genetic screens in mice uncover mediators and suppressors of metastatic reactivation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 16532-16537.	7.1	49
24	NOXA genetic amplification or pharmacologic induction primes lymphoma cells to BCL2 inhibitor-induced cell death. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 12034-12039.	7.1	41
25	O-GlcNAcase targets pyruvate kinase M2 to regulate tumor growth. <i>Oncogene</i> , 2020, 39, 560-573.	5.9	39
26	Characterization of a set of tumor suppressor microRNAs in T cell acute lymphoblastic leukemia. <i>Science Signaling</i> , 2014, 7, ra111.	3.6	36
27	Comparison of broad-spectrum antiviral activities of the synthetic rocaglate CR-31-B (âˆ™) and the eIF4A-inhibitor Silvestrol. <i>Antiviral Research</i> , 2020, 175, 104706.	4.1	36
28	The serine hydroxymethyltransferase-2 (SHMT2) initiates lymphoma development through epigenetic tumor suppressor silencing. <i>Nature Cancer</i> , 2020, 1, 653-664.	13.2	35
29	Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265 mutations. <i>JCI Insight</i> , 2017, 2, e90196.	5.0	34
30	Frequent disruption of the RB pathway in indolent follicular lymphoma suggests a new combination therapy. <i>Journal of Experimental Medicine</i> , 2014, 211, 1379-1391.	8.5	32
31	c-MYC regulates mRNA translation efficiency and start-site selection in lymphoma. <i>Journal of Experimental Medicine</i> , 2019, 216, 1509-1524.	8.5	32
32	Targeted PET imaging strategy to differentiate malignant from inflamed lymph nodes in diffuse large B-cell lymphoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E7441-E7449.	7.1	28
33	Identification of Novel Therapeutic Targets for Fibrolamellar Carcinoma Using Patient-Derived Xenografts and Direct-from-Patient Screening. <i>Cancer Discovery</i> , 2021, 11, 2544-2563.	9.4	27
34	The rocaglate CR-31-B (âˆ™) inhibits SARS-CoV-2 replication at non-cytotoxic, low nanomolar concentrations in vitro and ex vivo. <i>Antiviral Research</i> , 2021, 186, 105012.	4.1	26
35	Targeting eIF4A-Dependent Translation of KRAS Signaling Molecules. <i>Cancer Research</i> , 2021, 81, 2002-2014.	0.9	17
36	Noncovalent inhibitors reveal BTK gatekeeper and auto-inhibitory residues that control its transforming activity. <i>JCI Insight</i> , 2019, 4, .	5.0	17

#	ARTICLE	IF	CITATIONS
37	NRF2 Activation Confers Resistance to eIF4A Inhibitors in Cancer Therapy. <i>Cancers</i> , 2021, 13, 639.	3.7	13
38	A Cell Engineering Strategy to Enhance the Safety of Stem Cell Therapies. <i>Cell Reports</i> , 2014, 8, 1677-1685.	6.4	9
39	Ectopic activation of the miR-200c/EpCAM axis enhances antitumor T cell responses in models of adoptive cell therapy. <i>Science Translational Medicine</i> , 2021, 13, eabg4328.	12.4	8
40	Transcriptional and Translational Dynamics of Zika and Dengue Virus Infection. <i>Viruses</i> , 2022, 14, 1418.	3.3	5
41	Rocaglates as Antivirals: Comparing the Effects on Viral Resistance, Anti-Coronaviral Activity, RNA-Clamping on eIF4A and Immune Cell Toxicity. <i>Viruses</i> , 2022, 14, 519.	3.3	4
42	Frequent 4EBP1 Amplification Induces Synthetic Dependence on FGFR Signaling in Cancer. <i>Cancers</i> , 2022, 14, 2397.	3.7	1
43	Genomic Studies Indicate A Novel Combination Therapy For Follicular Lymphoma. <i>Molecular and Cellular Oncology</i> , 2014, 8, 00-00.	0.7	0
44	MicroRNAs Mediate Resistance to Tyrosine Kinase Inhibitors in Philadelphia-Positive B-ALL by Down-Regulating Key Tumor Suppressors. <i>Blood</i> , 2011, 118, 2553-2553.	1.4	0
45	Crebbp Mutations Disrupt Dynamic Enhancer Acetylation in B-Cells, Enabling HDAC3 to Drive Lymphomagenesis. <i>Blood</i> , 2016, 128, 735-735.	1.4	0